JOHN GRANDGENETT: Open Payments
NPI 1174537849 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$857 in 41 payments from 11 companies in 2025. Trend: 2023 $709 · 2024 $1,073 · 2025 $857
Food & beverage: $857
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $233 |
| Novo Nordisk Inc | 9 | $160 |
| ABBVIE INC. | 11 | $157 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Medtronic, Inc. | 1 | $54 |
| PFIZER INC. | 3 | $44 |
| Novartis Pharmaceuticals Corporation | 1 | $35 |
| Biogen, Inc. | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: Veozah, Wegovy, REXULTI, CAPLYTA, QULIPTA, SYMPLICITY G3, Ozempic, VRAYLAR.
Industry payments across NE — which companies pay providers there.
